Sugi Predict

Sugi Predict / Compounds / SCHEMBL506682

SCHEMBL506682

SCHEMBL506682

N#Cc1ccc(Br)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 2/20 0.54
▸ ALB P02768 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ CXCR2 P25025 4/20 0.50
▸ CXCR1 P25024 2/20 0.50
▸ CA12 O43570 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA3 P07451 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ CYP19A1 P11511 1/20 0.44
▸ MMP3 P08254 1/20 0.43
▸ GPR35 Q9HC97 1/20 0.40
▸ AR P10275 1/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ KDM1A O60341 2/20 0.38
▸ KDM1B Q8NB78 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91352 0.84 MEN1 (0.58) TTRALBMEN1KMT2ACXCR2
SCHEMBL11017920 0.80 MEN1 (0.52) TTRALBMEN1KMT2ACXCR2
SCHEMBL29449995 0.80 CA12 (0.52) TTRALBMEN1KMT2ACXCR2
SCHEMBL217250 0.80 CA12 (0.52) TTRALBMEN1KMT2ACXCR2
SCHEMBL23271632 0.78 CA12 (0.50) TTRALBMEN1KMT2ACXCR2
SCHEMBL28759539 0.78 CA12 (0.50) TTRALBMEN1KMT2ACXCR2
SCHEMBL34461940 0.78 CA12 (0.50) TTRALBMEN1KMT2ACXCR2
Lithium SCHEMBL29619850 0.78 CA12 (0.50) TTRALBMEN1KMT2ACXCR2
Bromide SCHEMBL28616524 0.78 CA12 (0.50) TTRALBMEN1KMT2ACXCR2
Lithium SCHEMBL29517077 0.78 CA12 (0.50) TTRALBMEN1KMT2ACXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118515534-B Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof 华南理工大学 2024-11-05 — — CN claimed
CN-118515534-A Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof 华南理工大学 2024-08-20 — — CN claimed
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
CN-118515534-B Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof 华南理工大学 2024-11-05 — — CN disclosed
CN-118515534-A Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof 华南理工大学 2024-08-20 — — CN disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 — — US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 — — CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 — — US disclosed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 — — US disclosed
CN-115996910-A Aryl or heteroaryl derivatives 帝人制药株式会社 2023-04-21 — — CN disclosed
CN-101282934-A Triarylcarboxylic acid derivatives ASTELLAS PHARMA INC (JP) 2008-10-08 — — CN disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 — — CN disclosed
CN-1869027-A Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles UNIV NORTH CAROLINA (US) 2006-11-29 — — CN disclosed
US-20060264487-A1 Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles TIDWELL RICHARD R 2006-11-23 — — US disclosed
EP-1720836-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-11-15 — — EP disclosed
EP-1719767-A1 Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles The University of North Carolina at Chapel Hill (US) 2006-11-08 — — EP disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE ARRB1, NR3C2, TRPC6 TTR 1970/4885ALB 1135/4885MEN1 1218/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 TTR 2559/4885ALB 4881/4885MEN1 4196/4885
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 TTR 3916/4885ALB 4170/4885MEN1 4777/4885
US-20060264487-A1 Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles PFAS, DHPS, DDO TTR 4160/4885ALB 2685/4885MEN1 2096/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 TTR 4664/4885ALB 4614/4885MEN1 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.